Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment
Maria Cecilia Bahit1, Christopher B Granger, Lars Wallentin
1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA. bahit001@mc.duke.edu
Insights
Patients with acute coronary syndromes face a high risk of thrombotic events weeks after initial treatment. Further research into extended antithrombotic therapies is crucial for reducing mortality and myocardial infarction.
Area of Science:
- Cardiology
- Thrombosis Research
Background:
- Acute coronary syndromes (ACS), including unstable angina and myocardial infarction, stem from thrombosis on ruptured atherosclerotic plaques.
- Antithrombotic therapy during the acute phase, using agents like aspirin and heparin, significantly lowers the risk of death or myocardial infarction (MI).
Purpose of the Study:
- To investigate the extended high-risk period for thrombotic events post-ACS presentation, lasting several weeks.
- To review current and potential treatments aimed at mitigating these post-ACS thrombotic risks.
Main Methods:
- Review of clinical studies on antithrombotic strategies for acute coronary syndromes.
- Analysis of treatment durations and drug classes including antiplatelet agents, anticoagulants, and glycoprotein IIb/IIIa inhibitors.
Main Results:
- Over half of thrombotic events occur after the initial 3-5 day in-hospital treatment period.
- Aspirin and clopidogrel demonstrate efficacy in risk reduction; dalteparin shows benefit for at least one month.
- Warfarin combined with aspirin has yielded disappointing results, and oral glycoprotein IIb/IIIa inhibitors may increase mortality risk.
Conclusions:
- Reducing the risk of thrombotic events in the weeks following acute coronary syndrome presentation remains a critical clinical objective.
- Optimizing antithrombotic strategies beyond the acute phase is essential for improving long-term patient outcomes.
Background And Results:
Acute coronary syndromes (unstable angina and acute myocardial infarction) are generally caused by thrombosis over a disrupted atherosclerotic plaque. During the acute phase, antithrombotic therapy (including aspirin and heparin) has been shown to reduce the risk of death or myocardial infarction (MI). The purpose of this review is to examine the high-risk period for clinical thrombotic events that extends for several weeks after presentation and to review the treatments aimed at reducing these events.
Results:
More than half of clinical events reported during the first month occur after the first 3 to 5 days that comprise the standard in-hospital treatment period. Several different antithrombotic approaches have been tested, including longer duration of antiplatelet therapy, anticoagulant treatment, and oral glycoprotein (GP) IIb/IIIa inhibitors. Aspirin is effective at reducing risk, and clopidogrel provides additional benefit, as does dalteparin for at least the first month. Warfarin in addition to aspirin, while generally disappointing, has not been adequately tested at higher doses. Oral GP IIb/IIIa inhibitors cause a paradoxic increased risk of death for unclear reasons.
Conclusion:
Further reduction of risk during the weeks after presentation with acute coronary syndromes remains an important therapeutic goal.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Acute Coronary Syndrome V: Nursing Management